Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network
A. Sanz, Rosa Ayala, Gema Hernández, Nixma Eljure Lopez, Daniel Gil-Alós, Raquel Salcedo Gil, Rafael Colmenares, Gonzalo Carreño‐Tarragona, José María Sánchez‐Pina, Rafael Alonso, Noelia García Barrio, David Pérez-Rey, L. Meloni, María Calbacho, J. Cruz-Rojo, Miguel Pedrera‐Jiménez, Pablo Serrano Balazote, J. de la Cruz, Joaquín Martínez‐López
Abstract
The natural history of chronic myeloid leukemia (CML) experienced a major change in the early 2000s with the development of the first BCR-ABL1 specific tyrosine kinase inhibitors (TKIs) [ 1 , 2 ]; however, there is limited supporting evidence from electronic health records (i.e., real-world data [RWD]). TriNetX is a global health research platform that provides researchers access to electronic medical records from healthcare organizations (HCOs) for conducting research studies. Our goal was to better define the current survival landscape of CML and the long-term toxicities so that we can have a better and updated understanding of the disease and the actual clinical practice in local, regional, and global settings.